Poor
Not Aligned
Patient Risk:
Medium
Summary
Most claims cannot be verified against the supplied TYGACIL label excerpts (which only include boxed warning/all-cause mortality and mortality imbalance in hospital/ventilator-associated pneumonia). Several claims about specific indications and liver adverse events are not supported by the provided label text.
Category Scores
Accurate Statements
The label includes an all-cause mortality increase in TYGACIL-treated patients versus comparator with an adjusted risk difference of 0.6% (95% CI 0.1, 1.2).
Boxed Warning (5.1) LABEL TEXT; Section 5.1; Section 6.1
Unsupported Statements
Tigecycline is a broad-spectrum antibiotic.
No such description appears in the provided label excerpts.
Tigecycline is used to treat community-acquired pneumonia.
No indication statement for community-acquired pneumonia is present in the provided label excerpts.
Tigecycline is used to treat skin and soft tissue infections.
The provided excerpts do not include the Indications and Usage section text listing skin and soft tissue infection treatment.
Tigecycline is used to treat intra-abdominal infections.
The provided excerpts do not include the Indications and Usage section text listing intra-abdominal infection treatment.
Tigecycline can cause liver-related adverse events (LRAEs), including elevated liver enzymes, jaundice, and liver failure.
No liver-related adverse event content appears in the provided label excerpts.
In a study, 12.1% of patients treated with tigecycline experienced LRAEs.
No such percentage or LRAE study data is present in the provided label excerpts.
In that study, the majority of tigecycline-associated LRAEs occurred in patients over the age of 65.
No age-stratified LRAE data is present in the provided label excerpts.
Elderly patients are more likely to experience LRAEs with tigecycline due to declining liver function.
No labeling support is present in the provided excerpts for LRAE risk by age or a mechanism related to declining liver function.
Renal impairment is a risk factor for LRAEs with tigecycline.
No labeling support is present in the provided excerpts for LRAE risk associated with renal impairment.
Patients with kidney disease may have an increased risk of LRAEs with tigecycline due to altered tigecycline metabolism.
No labeling support is present in the provided excerpts for this claim or any metabolism rationale.
Concurrent medications that affect liver function, such as statins or anticonvulsants, may increase the risk of LRAEs with tigecycline.
No labeling support is present in the provided excerpts for drug-interaction-related LRAE risk (and no interaction section text is provided).
Underlying liver disease is a risk factor for LRAEs with tigecycline.
No labeling support is present in the provided excerpts.
A case report described tigecycline-related liver failure in an 85-year-old patient after receiving tigecycline for 14 days.
No case report details are present in the provided label excerpts.
In the described case report, the patient developed elevated liver enzymes, jaundice, and liver failure after tigecycline administration.
No such case report details are present in the provided label excerpts.
In that case report, the patient required hospitalization and supportive care and a liver transplantation.
No such case report details are present in the provided label excerpts.
Healthcare providers should monitor patients for signs of LRAEs with tigecycline, including elevated liver enzymes, jaundice, and liver failure.
No monitoring recommendation for LRAEs is present in the provided label excerpts.
Contradictions
Important Omissions
The provided AI claims do not address the boxed warning content and major label safety messaging in the supplied excerpts (all-cause mortality; reserve use when alternative treatments are not suitable; hospital/ventilator-associated pneumonia mortality/cure rate findings).
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Because many claims (especially liver-related adverse events, risk factors, and monitoring) are unsupported by the supplied label excerpts, the response could mislead regarding what the FDA-approved label specifically emphasizes. However, it does not directly contradict the provided boxed-warning mortality information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are not supported by the provided TYGACIL label excerpts; the response also fails to reflect the supplied boxed warning and mortality/limitations of use text.
Suggested Improvement
Limit claims to the supplied label excerpts (boxed warning/all-cause mortality and mortality imbalance in hospital/ventilator-associated pneumonia) unless additional prescribing-information sections (e.g., Indications and Usage, Warnings/Precautions for LRAEs, Adverse Reactions, Drug Interactions, and Monitoring) are provided for verification.